FDA PMA FDA Class 3 Approved 🇺🇸 United States

Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)

PMA: P100031 · Decision Jun 22, 2011
Classifications
1
FEI Numbers
27
Registration Numbers
27

Basic Information

Device Name
Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
Trade Name
ELECSYS ANTI-HBC IMMUNOASSAY & ELECSYS PRECICONTROL ANTI-HBC
PMA Number
P100031
Device Class
FDA Class 3
Product Code
LOM
Generic Name
Test, hepatitis b (b core, be antigen, be antibody, b core igm)
Medical Specialty
Unknown
Advisory Committee
Microbiology
Decision
Approved
Decision Code
APPR
Decision Date
June 22, 2011
Date Received
July 30, 2010
Expedited Review
N
Docket Number
11M-0502

Advisory Committee Statement

APPROVAL FOR THE ELECSYS ANTI-HBC IMMUNOASSAY & ELECSYS PRECICONTROL ANTI-HBC FOR USE ON THE MODULAR ANALYTICS E170 IMMUNOASSAY ANALYZER. THIS DEVICE IS INDICATED FOR THE IN VITRO QUALITATIVE DETERMINATION OF TOTAL ANTIBODIES TO HEPATITIS B CORE ANTIGEN (ANTI-HBC) IN HUMAN SERUM AND PLASMA (LITHIUM-HEPARIN, SODIUM-CITRATE, K2-EDTA) IN ADULT PATIENTS WITH THE SYMPTOMS OF HEPATITIS OR WHO MAY BE AT RISK FOR HEPATITIS B (HBV) INFECTION. THE DETECTION OF TOTAL ANTI-HBC IS INDICATIVE OF A LABORATORY DIAGNOSIS FOR HBV INFECTION. FURTHER HBV SEROLOGICAL MARKER TESTING IS REQUIRED TO DEFINE THE SPECIFIC DISEASE STATE. THE ELECSYS ANTI-HBC IMMUNOASSAY'S PERFORMANCE HAS NOT BEEN ESTABLISHED FOR THE MONITORING HBV DISEASE OR THERAPY. THE ELECTRO- CHEMILUMINESCENCE IMMUNOASSAY "ECLIA" IS INTENDED FOR USE ON THE MODULAR ANALYTICS EI70 IMMUNOASSAY ANALYZER. THE ELECSYS PRECI-CONTROL ANTI-HBC IS USED FOR QUALITY CONTROL OF THE ELECSYS ANTI-HBC IMMUNOASSAY ON THE MODULAR ANALYTICS E170 IMMUNOASSAY ANALYZER.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LOM Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)